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a b s t r a c t
A straightforward route is proposed for the multi-gram scale synthesis of heterobifunctional poly(ethyl-
ene glycol) (PEG) oligomers containing combination of triethyloxysilane extremity for surface modiﬁca-
tion of metal oxides and amino or azido active end groups for further functionalization. The suitability of
these PEG derivatives to be conjugated to nanomaterials was shown by pegylation of ultrasmall super-
paramagnetic iron oxide (USPIO) nanoparticles (NPs), followed by functionalization with small peptide
ligands for biomedical applications.
 2013 Elsevier Ltd. All rights reserved.
Poly(ethylene glycol) (PEG) has recently emerged as oligomer of
choice for diverse applications in biomedical areas, such as surface
modiﬁcation, functionalization of nanomaterials and biomole-
cules.1 Due to the remarkable properties of PEG oligomers, includ-
ing nontoxicity, nonimmunogenicity, biocompatibility and high
solubility in many organic solvents and in aqueous media, pegyla-
tion has been extensively used to increase the performance of sur-
faces and macromolecules. In particular, pegylated nanocarriers
demonstrated high efﬁciency for the improved delivery of small
molecule effectors,2–4 proteins5,6 or DNA7,8 to their target recep-
tors. These sophisticated applications require the access to PEG
molecules presenting two orthogonal and reactive end functional-
ities.1 The most common route to these hetero-bifunctional PEG re-
lies on anionic polymerization of ethylene oxide from functional
initiators followed by post-modiﬁcation of the terminal hydroxyl
group.9–14 Other techniques include the modiﬁcation of commer-
cially available, but expensive, modiﬁed PEG molecules15–17 or
the sequential and unsymmetrical alteration of end hydroxyl
groups of linear PEG. In particular, the use of tosylate activating
groups was reported by Mahou and Wandrey18 for the generation
of diverse heterotelechelic PEG oligomers. Polymer-supported pathway was also reported for the production of pyridyldithio acti-
vated PEG.19
We present herein an alternative approach for the multi-gram
scale production of azido- and amino-silanized PEG molecules
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Scheme 1. Synthesis of heterobifunctional PEG derivatives.
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and their conjugation to ultrasmall superparamagnetic iron oxide
(USPIO) nanoparticles (NPs) as model nanoparticles to highlight
the potential of these heterobifunctional systems for the function-
alization of nanomaterials. PEG-functionalized USPIO NPs (cNPs)
were further conjugated with a c(RGDfK) moiety for the speciﬁc
targeting of the cell membrane receptor avb3 integrin.20–25
The synthesis of PEG tethers for surface modiﬁcation of NPs re-
quires a functional group at one end for conjugation to the material
surface and a reactive group at the other end for functionalization
with bioactivemolecules. The preparation of a-triethoxysilyl-x-amino
PEG was thus envisaged for surface modiﬁcation of USPIO NPs (see
Supporting information for experimental procedures and charac-
terizations). The sequential and unsymmetrical alteration of the
end hydroxyl groups of linear PEG (PEG-2000, 2000 MW, 45 units)
was achieved through semi-reduction of key intermediate 3
(Scheme 1). This diazido PEG derivative was obtained by ditosyla-
tion of PEG-2000 followed by nucleophilic displacement with so-
dium azide. This sequence could be achieved on up to 100 g of
PEG starting material with ﬁltration of ditosylate 2 on silica gel
as only puriﬁcation step. Several reports proposed monotosylation
of PEG18,26,27 as desymmetrization step but we experienced difﬁ-
culties to obtain pure monotosylate intermediate on large scale
and thus opted for monoreduction of 3 as desymmetrization path-
way. Treatment of diazide 3 with triphenylphosphine (1 equiv), in
acidic medium, afforded a-amino-x-azido PEG 4 in high yield and
excellent purity. The amino end was further reacted with succinic
anhydride in almost quantitative yield, followed by coupling with
3-amino-propyltriethoxysilane to provide intermediate 6. The end
azido group was reduced by hydrogenolysis to deliver a-triethoxy-
silyl-x-amino PEG 7 in quantitative yield.
This straightforward route gives access to heterobifunctional
PEG derivatives suitable for further conjugation to nanomaterials
as the silyl functionality is a very efﬁcient anchoring group for
the pegylation of metal oxides, leading to highly stable coating in
aqueous media.28 In addition, the amino or azido end groups can
be coupled to biomolecules though peptide type coupling or cop-
per-catalyzed [3+2] cycloadditions (click reactions). Other anchor-
ing moieties such as carboxylates, phosphonates and catechol
ligands, in particular dopamine-based derivatives, have been con-
jugated to nanoparticulate iron oxides29 to increase long-term col-
loidal stability in biological medium30 and to display
multifunctional surfaces.31 Nevertheless, Fe(III)-mediated oxida-
tion of catechol ligands might induce loss of colloidal stability
and produce cytotoxic iron–quinone complexes.32
The suitability of heterobifunctional PEG molecules 6 and 7 for
the pegylation of metal oxide NPs was addressed using USPIO NPs.
A suspension of magnetite (Fe3O4) NPs (PlasmaChem, 7% nano-
suspension in water, average particle core size 8 ± 3 nm), in a mix-
ture of EtOH/toluene (1:1), was ultrasonicated in the presence of
AcOH and PEG derivatives 6 and 7 (1:1). After thorough washings
with EtOH, using magnetic immobilization to separate the NPs
from the supernatant, the coated NPs (cNPs) were suspended in
EtOH (Scheme 2).
The cNPs were characterized for their size and surface charge by
measurement of mean hydrodynamic diameter (dynamic light
scattering) and zeta potential. Upon coating, the zeta potential va-
lue shifted from 25.0 ± 4.8 to +41.1 ± 0.4 mV and the mean
hydrodynamic diameter increased from 39.1 ± 0.8 to 81 ± 5.6 nm
(Table 1, entries 1 and 2 and see Supplementary information). In
addition, FT-IR spectrum of cNPs displayed bands at 3450–3350
and around 2100 cm1 characteristic for amine and azide function-
alities, respectively (Fig. 1). These results provide evidence for sil-
anization of magnetite NPs with heterobifunctional PEG molecules
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Scheme 2. Silanization of bare magnetite NPs.
Table 1
Mean DLS size (size distribution by number) and surface charge (zeta potential) of
coated magnetite NPs
Entry Ratio 6:7 DLS (nm) Zeta potential (mV)
1 0:0 39.1 ± 0.8 25.0 ± 4.8
2 50:50 81.0 ± 5.6 +41.1 ± 0.4
3 100:0 317.1 ± 5.9 +29.7 ± 1.7
4 0:100 49.2 ± 7.6 +37.3 ± 0.6
Figure 1. FT-IR of USPIO NPs coated with a (1:1) mixture of 6 and 7 (red) and functionalized NPs after click-reaction (black).
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6 and 7. Upon pegylation with PEG oligomer 6 only, the resulting
cNPs displayed a broad range of hydrodynamic diameters due to
the formation of aggregates (Table 1, entry 3). The concomitant
surface modiﬁcation by both oligomers 6 and 7 resulted in polydis-
perse cNPs due to the presence of amine functionalities (Table 1,
entry 4). A (1:1) ratio of PEG derivatives 6 and 7 was thus selected
to maintain a small hydrodynamic radius of the resulted cNPs and
to display reactive surface azides for further functionalization.
In order to assess the suitability of the coated magnetite NPs for
biomedical applications, the stability of surface coating with a
(1:1) mixture of PEG derivatives 6 and 7 was evaluated at limit
pH values encountered in cell culture media and biological envi-
ronment. cNPs were suspended for 72 h in buffered solutions at
pH 4 (phosphate buffer) and pH 8 (25 mM Tris–HCl adjusted with
2 M NaOH). After washing with EtOH, surface charge of the result-
ing nanoparticles was analyzed and resulted in zeta potential val-
ues of +26.0 ± 0.2 and +29.7 ± 6.1 mV, respectively. These results
gave evidence for stability of the surface coating in the range of
pHs relevant for biomedical applications.
Conjugation to targeting entities was then investigated using
the azide moieties as reactive partners for click reaction. The prep-
aration of cRGDfK (8) was performed by solid phase peptide syn-
thesis as previously described.33 The introduction of an alkynyl
moiety was carried out by coupling with activated ester of penty-
noic acid to afford intermediate 9 in 61% yield (Scheme 3). The
azide-alkyne Huisgen’s cycloaddition reaction was designed to oc-
cur at the interface of azide-PEG coating of the NPs suspended in
H2O. Ligand 9, dissolved in DMF, was added to a suspension of cNPs
and the mixture was ultrasonicated for 12 h in the presence of cop-
per sulfate and sodium ascorbate. The remaining copper species
were removed by treatment with Cyclam,34 followed by thorough
washing with methanol, using magnetic immobilization of the
functionalized NPs.
The conjugation of cRGDfK to the surface of cNPs was moni-
tored by FT-IR (Fig. 1). The presence of the peptide ligand was evi-
denced by bands at 1640 and 1550 cm1, while the formation of
the triazole unit was evidenced by the apparition of the C–N
stretching band at 1360 cm1.35 The conjugated NPs were also
characterized for their mean hydrodynamic diameter and surface
charge which were measured at 137 ± 29.5 nm and +25 ± 0.2 mV,
respectively.
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Scheme 3. Functionalization of the PEG-magnetite NPs with the avb3 integrin-targeting ligand.
0
20
40
60
80
100
120
uNPs cNPs
%
 o
f h
em
ol
ys
is
Figure 2. Hemolytic effect of bare and functionalized USPIO NPs on human red
blood cells. Human red blood cells were exposed for 2 h either to unfunctionalized
(uNPs) or to PEG-functionalized USPIO (cNPs) at a concentration of 50 lg/mL, then
the release of hemoglobin was assessed. Results are the mean ± SD of triplicates of
two independent experiments. NPs-exposed cells were compared to unexposed
cells using a Student t-test: ⁄⁄⁄P < 0.001.
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The biocompatibility of the USPIO NPs functionalized with the
PEG oligomers 6 and 7 was assessed using the hemolytic assays.36
The hemolytic potential, deﬁned as the lysis of red blood cells, is an
adverse event which might occur upon exposure to NPs.37 Un-
coated USPIO NPs showed a high hemolytic potential, causing the
lysis of 100% of human red blood cells after 2 h exposure (Fig. 2).
Functionalization of the USPIO NPs with PEG molecules 6 and 7
drastically improved the biocompatibility of the resulting nanom-
aterials as no hemolytic effect could be observed after 2 h exposure
at a concentration of 50 lg/mL. The same behavior was observed
for the USPIO NPs functionalized with the avb3 integrin-targeting
cRGDfK ligand (data not shown).
As the avb3 integrin was reported as an important biomarker for
the detection of primary cancer and metastasis,38 we further ad-
dressed the ability of functionalized USPIO NPs to speciﬁcally tar-
get human derived cancer cells expressing this membrane
receptor, through recognition of the cyclo [Arg-Gly-Asp-D-Phe-
Lys] sequence at the surface of NPs. The human PC3 prostate can-
cer cells, which express the avb3 integrin,39 and the MCF-7 breast
cancer cells, which do not express the avb3 integrin,23 were se-
lected as positive and negative control cells, respectively. The pres-
ence of USPIO NPs was detected histologically using the Prussian
blue staining.40 None of the cells recognized cNPs. Upon exposure
to USPIO NPs functionalized with c(RGDfK), PC3 cells showed a
clear binding of the c(RGDfK)-functionalized USPIO NPs, close to
the cell adhesive contact (Fig. 3). Notably, a similar treatment of
MCF-7 cells did not result in any signiﬁcant binding of the func-
tionalized NPs.
In summary, a fast and convenient large scale synthesis of hete-
robifunctional PEG oligomers suitable for silanization of USPIO NPs
was developed. Differentiation of the hydroxyl ends of commercial
PEG 2000 was achieved through selective reduction of a diazide
intermediate. The resulting PEG derivatives allowed both the mod-
iﬁcation of the surface of metal oxide nanoparticles and the conju-
gation of bio-active molecules. For instance, magnetite NPs were
efﬁciently pegylated with oligomers 6 and 7, allowing further con-
jugation with c(RGDfK) derivative 9 through click reaction. The
resulting functionalized nanoparticles did not show any hemolytic
effect on human red blood cells and demonstrated speciﬁc binding
to human cancer cells expressing the avb3 integrin, an important
biomarker of human cancer. In view of the many imaging applica-
tions of iron oxide-based nanomaterials,41–46 the functionalization
procedures described herein offers new possibilities for biomedical
applications based on NPs.
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